Thanks to the now-public interest of Valeant (NYSE: VRX ) in making Allergan (NYSE: AGN )
its own, not to mention the vocal and financial support of Pershing
Square and Bill Ackman, the status quo is gone for good at Allergan.
Good first quarter results and improved guidance for the year were both
nice to see, but Allergan is going to have to do a lot more to convince
its shareholders that a plan for the future that excludes selling out to
Valeant has their best interests at heart.
Read more here:
Can Allergan Remain Independent of Valeant?
No comments:
Post a Comment